董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Susan Mahony | 女 | Independent Director | 58 | 51.44万美元 | 未持股 | 2023-05-31 |
| James Shannon | 男 | Independent Director | 66 | 51.06万美元 | 未持股 | 2023-05-31 |
| Michael Grey | 男 | Independent Director | 70 | 55.12万美元 | 未持股 | 2023-05-31 |
| William F. Daniel | 男 | Independent Director | 71 | 52.25万美元 | 未持股 | 2023-05-31 |
| Timothy P. Walbert | 男 | Chairman, President and Chief Executive Officer | 56 | 2010.39万美元 | 未持股 | 2023-05-31 |
| Jeff Himawan | 男 | Independent Director | 58 | 50.44万美元 | 未持股 | 2023-05-31 |
| Gino Santini | 男 | Independent Director | 66 | 49.50万美元 | 未持股 | 2023-05-31 |
| Pascale Witz | 女 | Independent Director | 56 | 49.62万美元 | 未持股 | 2023-05-31 |
| H. Thomas Watkins | 男 | Independent Director | 70 | 50.62万美元 | 未持股 | 2023-05-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael A. DesJardin | 男 | Executive Vice President, Technical Operations and Corporate Quality | 65 | 未披露 | 未持股 | 2023-05-31 |
| Andy Pasternak | 男 | Executive Vice President, Chief Strategy Officer | 52 | 675.28万美元 | 未持股 | 2023-05-31 |
| Sean M. Clayton | 男 | Executive Vice President, General Counsel | 44 | 1087.22万美元 | 未持股 | 2023-05-31 |
| Aaron L. Cox | 男 | Executive Vice President, Chief Financial Officer | 40 | 717.45万美元 | 未持股 | 2023-05-31 |
| Elizabeth H.Z. Thompson | 女 | Executive Vice President, Research and Development | 48 | 848.10万美元 | 未持股 | 2023-05-31 |
| Timothy P. Walbert | 男 | Chairman, President and Chief Executive Officer | 56 | 2010.39万美元 | 未持股 | 2023-05-31 |
| Jeffrey W. Sherman | 男 | Executive Vice President, Chief Medical Officer | 68 | 526.13万美元 | 未持股 | 2023-05-31 |
董事简历
中英对照 | 中文 | 英文- Susan Mahony
-
Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
Susan Mahony,serves on the board of directors of Zymeworks Inc., a public biopharma company and Assembly Biosciences, Inc., a public biotechnology company. She served on the board of directors of Vifor Pharma AG, a public pharmaceutical company, from May 2019 until its acquisition by CSL Limited in August 2022. Previously, Dr. Mahony served as senior vice president and president of Lilly Oncology and was a member of the executive committee at Eli Lilly and Company from 2009 until her retirement in August 2018. Prior to that, Dr. Mahony served in a variety of leadership roles at Eli Lilly and Company, including senior vice president, human resources and diversity; president and general manager, Lilly Canada; and executive director, global brand development. Dr. Mahony worked in sales and marketing at Bristol-Myers Squibb Company from 1995 to 2000, at Amgen Limited from 1991 to 1995, and at Schering Plough from 1989 to 1991. Dr. Mahony also serves on the board of Chordoma Foundation, a nonprofit organization dedicated to improving the lives of those affected by chordoma. She earned bachelor of science and doctor of philosophy degrees in pharmacy from Aston University, as well as a master of business administration degree from London Business School. She was awarded an honorary doctorate from Aston University. - Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
- Susan Mahony,serves on the board of directors of Zymeworks Inc., a public biopharma company and Assembly Biosciences, Inc., a public biotechnology company. She served on the board of directors of Vifor Pharma AG, a public pharmaceutical company, from May 2019 until its acquisition by CSL Limited in August 2022. Previously, Dr. Mahony served as senior vice president and president of Lilly Oncology and was a member of the executive committee at Eli Lilly and Company from 2009 until her retirement in August 2018. Prior to that, Dr. Mahony served in a variety of leadership roles at Eli Lilly and Company, including senior vice president, human resources and diversity; president and general manager, Lilly Canada; and executive director, global brand development. Dr. Mahony worked in sales and marketing at Bristol-Myers Squibb Company from 1995 to 2000, at Amgen Limited from 1991 to 1995, and at Schering Plough from 1989 to 1991. Dr. Mahony also serves on the board of Chordoma Foundation, a nonprofit organization dedicated to improving the lives of those affected by chordoma. She earned bachelor of science and doctor of philosophy degrees in pharmacy from Aston University, as well as a master of business administration degree from London Business School. She was awarded an honorary doctorate from Aston University.
- James Shannon
-
James Shannon目前担任Mannkind Corporation（一家专注于糖尿病治疗的公共生物制药公司）的董事会主席，并担任ProQR Therapeutics NV（一家公共生物技术公司）的董事会主席。从2012年5月到2015年3月，他曾担任GlaxoSmithKline GSK公司（公共生物制药公司）的首席医疗官，在那里他曾负责患者安全、一般医疗治理、医疗道德和诚信事务，医疗信息以及与正在开发或市场上的任何GSK药物有关的涉及人体受试者的调查。在此之前，Shannon博士在Novartis（一家上市制药公司）工作了十多年。在公司的最后一个职位上，作为制药开发的全球主管，他负责Novartis&8217；的所有开发活动，从临床前到4期，并监督大约40亿美元的年度开发预算。Shannon博士在北爱尔兰贝尔法斯特皇后大学（Queen&8217；s University）获得科学和医学学位。他也担任Kyowa Kirin（NA）（私人生物制药公司和Kyowa Kirin的子公司）的董事会主席，以及Immodulon Therapeutics Limited（私人生物制药公司）、Leyden Labs（私人生物制药公司）和MyTomorrows的董事会成员，一个基于健康的私人平台，与药物开发商合作，为已用尽所有其他选择的患者提供早期治疗。
James Shannon,currently serves as chairman of the board of directors of MannKind Corporation, a public biopharma company focused on treatments for diabetes, and on the board of directors of ProQR Therapeutics NV, a public biotechnology company. From May 2012 to March 2015, Dr. Shannon served as the chief medical officer of GlaxoSmithKline (GSK), a public biopharma company, where he was responsible for matters of patient safety, general medical governance, medical ethics and integrity, medical information as well as investigations involving human subjects relating to any GSK medicine in development or on the market. Prior to that, Dr. Shannon spent more than a decade with Novartis, a public pharmaceutical company. In his last role with the company, as global head of pharma development, he was responsible for all of Novartis's development activities, from pre-clinical through Phase 4, and oversaw an annual development budget of approximately $4 billion. Dr. Shannon received his science and medical degrees from Queen's University in Belfast, Northern Ireland. He also serves as chairman of the board of directors of Kyowa Kirin (NA), a private biopharma company and subsidiary of Kyowa Kirin, and on the boards of directors of Leyden Labs, a private biopharma company, and MyTomorrows, a private health-based platform that collaborates with drug developers to provide early access to treatments for patients who have exhausted all other options. - James Shannon目前担任Mannkind Corporation（一家专注于糖尿病治疗的公共生物制药公司）的董事会主席，并担任ProQR Therapeutics NV（一家公共生物技术公司）的董事会主席。从2012年5月到2015年3月，他曾担任GlaxoSmithKline GSK公司（公共生物制药公司）的首席医疗官，在那里他曾负责患者安全、一般医疗治理、医疗道德和诚信事务，医疗信息以及与正在开发或市场上的任何GSK药物有关的涉及人体受试者的调查。在此之前，Shannon博士在Novartis（一家上市制药公司）工作了十多年。在公司的最后一个职位上，作为制药开发的全球主管，他负责Novartis&8217；的所有开发活动，从临床前到4期，并监督大约40亿美元的年度开发预算。Shannon博士在北爱尔兰贝尔法斯特皇后大学（Queen&8217；s University）获得科学和医学学位。他也担任Kyowa Kirin（NA）（私人生物制药公司和Kyowa Kirin的子公司）的董事会主席，以及Immodulon Therapeutics Limited（私人生物制药公司）、Leyden Labs（私人生物制药公司）和MyTomorrows的董事会成员，一个基于健康的私人平台，与药物开发商合作，为已用尽所有其他选择的患者提供早期治疗。
- James Shannon,currently serves as chairman of the board of directors of MannKind Corporation, a public biopharma company focused on treatments for diabetes, and on the board of directors of ProQR Therapeutics NV, a public biotechnology company. From May 2012 to March 2015, Dr. Shannon served as the chief medical officer of GlaxoSmithKline (GSK), a public biopharma company, where he was responsible for matters of patient safety, general medical governance, medical ethics and integrity, medical information as well as investigations involving human subjects relating to any GSK medicine in development or on the market. Prior to that, Dr. Shannon spent more than a decade with Novartis, a public pharmaceutical company. In his last role with the company, as global head of pharma development, he was responsible for all of Novartis's development activities, from pre-clinical through Phase 4, and oversaw an annual development budget of approximately $4 billion. Dr. Shannon received his science and medical degrees from Queen's University in Belfast, Northern Ireland. He also serves as chairman of the board of directors of Kyowa Kirin (NA), a private biopharma company and subsidiary of Kyowa Kirin, and on the boards of directors of Leyden Labs, a private biopharma company, and MyTomorrows, a private health-based platform that collaborates with drug developers to provide early access to treatments for patients who have exhausted all other options.
- Michael Grey
-
Michael Grey， 2005年加入董事会。自2011年2月起担任旭光制药公司（一家私人持有的生物技术公司）总裁和首席执行官；自2010年1月起担任Pappas投资公司（一家生命科学风险投资公司）投资合伙人。从2009年1月到2009年9月他担任Auspex制药有限公司（一家私人生物技术公司）总裁和首席执行官；从2005年1月他开始担任SGX制药有限公司（一家公开上市公司）总裁和首席执行官，直到2008年8月该公司被收购；之前他曾在2003年6月到2005年1月担任该公司总裁；2001年4月到2003年6月担任首席商务官。加入SGX制药公司之前，他曾担任Trega生物科学公司（一家生物技术公司）总裁、首席执行官和董事。从1994年11月到1998年8月他担任生物化学治疗公司（生化医药公司的医药经营部）总裁。在1994年期间，他担任安山公司（一家制药公司）总裁和首席运营官；从1974年到1993年他在葛兰素史克公司和葛兰素史克公司控股有限公司担任多个职位，包括企业发展副总裁的职位。现任海天制药公司（一家公众制药公司）和Selventa公司（一家医疗保健公司）董事。在过去五年他曾经担任两大上市公司董事，从1999年到2009年担任IDM Pharma公司董事；2001年到2010年担任艾琪尔顿制药有限公司董事。他持有英国诺丁汉大学化学理学学士学位。
Michael Grey,is Mirum Pharmaceuticals, Inc. co-founder and has served as Chair of the Board since January 2020. Mr. Grey previously served as Mirum Pharmaceuticals, Inc. Executive Chairman from March 2019 to December 2019 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer from Mirum Pharmaceuticals, Inc. inception in May 2018 to March 2019. Mr. Grey has served as Executive Chairman of Amplyx Pharmaceuticals, Inc., a privately-held pharmaceutical company, from January 2017 to April 2021, Reneo Pharmaceuticals, Inc., a privately-held pharmaceutical company, since December 2017, and Spruce Biosciences, Inc., a public biotechnology company, since April 2017. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion Pharmaceuticals, Inc., a pharmaceutical company (sold to Horizon Therapeutics plc in April 2020), from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx, and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001) and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey also serves on the boards of directors of public biotechnology and pharmaceutical companies Horizon Therapeutics plc and Spruce Biosciences, Inc., as well as privately-held biotechnology companies Plexium Inc. and Sorriso Pharmaceuticals, Inc. Mr. Grey received his B.S. in chemistry from the University of Nottingham in the United Kingdom. - Michael Grey， 2005年加入董事会。自2011年2月起担任旭光制药公司（一家私人持有的生物技术公司）总裁和首席执行官；自2010年1月起担任Pappas投资公司（一家生命科学风险投资公司）投资合伙人。从2009年1月到2009年9月他担任Auspex制药有限公司（一家私人生物技术公司）总裁和首席执行官；从2005年1月他开始担任SGX制药有限公司（一家公开上市公司）总裁和首席执行官，直到2008年8月该公司被收购；之前他曾在2003年6月到2005年1月担任该公司总裁；2001年4月到2003年6月担任首席商务官。加入SGX制药公司之前，他曾担任Trega生物科学公司（一家生物技术公司）总裁、首席执行官和董事。从1994年11月到1998年8月他担任生物化学治疗公司（生化医药公司的医药经营部）总裁。在1994年期间，他担任安山公司（一家制药公司）总裁和首席运营官；从1974年到1993年他在葛兰素史克公司和葛兰素史克公司控股有限公司担任多个职位，包括企业发展副总裁的职位。现任海天制药公司（一家公众制药公司）和Selventa公司（一家医疗保健公司）董事。在过去五年他曾经担任两大上市公司董事，从1999年到2009年担任IDM Pharma公司董事；2001年到2010年担任艾琪尔顿制药有限公司董事。他持有英国诺丁汉大学化学理学学士学位。
- Michael Grey,is Mirum Pharmaceuticals, Inc. co-founder and has served as Chair of the Board since January 2020. Mr. Grey previously served as Mirum Pharmaceuticals, Inc. Executive Chairman from March 2019 to December 2019 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer from Mirum Pharmaceuticals, Inc. inception in May 2018 to March 2019. Mr. Grey has served as Executive Chairman of Amplyx Pharmaceuticals, Inc., a privately-held pharmaceutical company, from January 2017 to April 2021, Reneo Pharmaceuticals, Inc., a privately-held pharmaceutical company, since December 2017, and Spruce Biosciences, Inc., a public biotechnology company, since April 2017. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion Pharmaceuticals, Inc., a pharmaceutical company (sold to Horizon Therapeutics plc in April 2020), from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx, and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001) and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey also serves on the boards of directors of public biotechnology and pharmaceutical companies Horizon Therapeutics plc and Spruce Biosciences, Inc., as well as privately-held biotechnology companies Plexium Inc. and Sorriso Pharmaceuticals, Inc. Mr. Grey received his B.S. in chemistry from the University of Nottingham in the United Kingdom.
- William F. Daniel
-
William F. Daniel自2014年9月起担任Horizon董事。Daniel，是一名注册董事和注册会计师，2013年5月被选为Institute of Directors of Ireland总裁；一开始于2010年6月被选为Institute of Directors of Ireland董事。2015年2月Daniel被任命为Malin Corporation plc（一家新建立的以巴塞尔为基地的全球生命科学公司）董事。最近，他从2001年12月开始担任Elan Corporation plc（一家生物技术公司）执行副总裁和公司秘书，一直担任到2013年12月Elan与Perrigo Company plc并购。他之前从2003年到2007年担任Elan执行董事；1994年加入该组织担任财务总监。Daniel之前从1990年到1992年担任Xtravision plc金融主管；在此之前他在An Post担任3年的金融主管。他也是Financial Executives's Association of Ireland前任总裁。Daniel毕业于University College Dublin，持有商业学位。
William F. Daniel,a chartered director and chartered accountant, is currently chair of the board of directors of Malin Corporation plc, an Ireland-based public global life sciences company. Mr. Daniel was president of the Institute of Directors of Ireland from May 2013 to May 2015, and he was originally elected to the board of the Institute of Directors in Ireland in June 2010. Prior to that, Mr. Daniel was executive vice president and company secretary of Elan Corporation plc, a public biotechnology company, and served in that role from December 2001 to December 2013, until the merger of Elan with Perrigo Company plc. He was previously an executive director of Elan between 2003 and 2007, having joined the organization as financial controller in 1994. Mr. Daniel graduated with a degree in commerce from University College Dublin. - William F. Daniel自2014年9月起担任Horizon董事。Daniel，是一名注册董事和注册会计师，2013年5月被选为Institute of Directors of Ireland总裁；一开始于2010年6月被选为Institute of Directors of Ireland董事。2015年2月Daniel被任命为Malin Corporation plc（一家新建立的以巴塞尔为基地的全球生命科学公司）董事。最近，他从2001年12月开始担任Elan Corporation plc（一家生物技术公司）执行副总裁和公司秘书，一直担任到2013年12月Elan与Perrigo Company plc并购。他之前从2003年到2007年担任Elan执行董事；1994年加入该组织担任财务总监。Daniel之前从1990年到1992年担任Xtravision plc金融主管；在此之前他在An Post担任3年的金融主管。他也是Financial Executives's Association of Ireland前任总裁。Daniel毕业于University College Dublin，持有商业学位。
- William F. Daniel,a chartered director and chartered accountant, is currently chair of the board of directors of Malin Corporation plc, an Ireland-based public global life sciences company. Mr. Daniel was president of the Institute of Directors of Ireland from May 2013 to May 2015, and he was originally elected to the board of the Institute of Directors in Ireland in June 2010. Prior to that, Mr. Daniel was executive vice president and company secretary of Elan Corporation plc, a public biotechnology company, and served in that role from December 2001 to December 2013, until the merger of Elan with Perrigo Company plc. He was previously an executive director of Elan between 2003 and 2007, having joined the organization as financial controller in 1994. Mr. Daniel graduated with a degree in commerce from University College Dublin.
- Timothy P. Walbert
-
Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania. - Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
- Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania.
- Jeff Himawan
-
Jeff Himawan，自2010年3月公司成立起在董事会任职，自2007年7月起在Horizon Pharma USA的董事会任职。1999年，他加入一家风投公司 Essex Woodlands Health Ventures, L.P.，在此他如今担任董事总经理。目前，他也在Catalyst生命科学有限公司、MediciNova有限公司、Light Sciences Oncology有限公司和Symphogen有限公司的董事会任职。先前，他从2001年起在 Iomai Corporation的董事会任职，直到2007年该公司被 Intercell AG收购。他联合创立了一家风投公司Seed-One Ventures，在此他从1996年至2001年担任董事总经理。他持有麻省理工大学生物学学士学位，哈佛大学生物化学和分离药理学博士学位。
Jeff Himawan,has been a managing director of Essex Woodlands Health Ventures, a venture capital firm, since 2004. Prior to that, he was an adjunct partner at Essex Woodlands from 1999 to 2001, and he was a venture partner from 2001 to 2004. Dr. Himawan co-founded Seed-One Ventures, an early-stage venture capital firm, where he served as a managing director from 1996 to 2001. Dr. Himawan serves on the board of directors of MediciNova, Inc., a public biopharma company(1), NexEos Bio, Inc., a private biotechnology company, and Light Sciences Oncology, Inc., a private biotechnology company. Previously, Dr. Himawan served on the board of directors of Catalyst Biosciences, Inc., a public biopharma company, from 2010 to 2020. He received a bachelor of science degree in biology from the Massachusetts Institute of Technology and a doctorate in biological chemistry and molecular pharmacology from Harvard University. - Jeff Himawan，自2010年3月公司成立起在董事会任职，自2007年7月起在Horizon Pharma USA的董事会任职。1999年，他加入一家风投公司 Essex Woodlands Health Ventures, L.P.，在此他如今担任董事总经理。目前，他也在Catalyst生命科学有限公司、MediciNova有限公司、Light Sciences Oncology有限公司和Symphogen有限公司的董事会任职。先前，他从2001年起在 Iomai Corporation的董事会任职，直到2007年该公司被 Intercell AG收购。他联合创立了一家风投公司Seed-One Ventures，在此他从1996年至2001年担任董事总经理。他持有麻省理工大学生物学学士学位，哈佛大学生物化学和分离药理学博士学位。
- Jeff Himawan,has been a managing director of Essex Woodlands Health Ventures, a venture capital firm, since 2004. Prior to that, he was an adjunct partner at Essex Woodlands from 1999 to 2001, and he was a venture partner from 2001 to 2004. Dr. Himawan co-founded Seed-One Ventures, an early-stage venture capital firm, where he served as a managing director from 1996 to 2001. Dr. Himawan serves on the board of directors of MediciNova, Inc., a public biopharma company(1), NexEos Bio, Inc., a private biotechnology company, and Light Sciences Oncology, Inc., a private biotechnology company. Previously, Dr. Himawan served on the board of directors of Catalyst Biosciences, Inc., a public biopharma company, from 2010 to 2020. He received a bachelor of science degree in biology from the Massachusetts Institute of Technology and a doctorate in biological chemistry and molecular pharmacology from Harvard University.
- Gino Santini
-
Gino Santini，自2012年3月起在董事会任职。目前，他在 AMAG Pharmaceuticals有限公司和Allena Pharmaceuticals有限公司董事会任职，且从Eli Lilly and Company（Lilly）退休，在此他工作了30年之久。在Lilly的任期内，他担任了责任越来越大的职务，包括许多国际地区的经理、女性健康特许的总裁，以及美国运营总裁。他在Lilly担任公司执行委员会董事及企业战略和业务发展高级副总裁。他精通四门语言，且持有博洛尼亚大学（ the University of Bologna）机械工程学士学位和罗切斯特大学（ the University of Rochester）工商管理硕士学位。
Gino Santini,currently serves on the boards of directors of Intercept Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., both of which are public biopharma companies. Mr. Santini also serves on the boards of directors of Artax Biopharma Inc. and Enalare Therapeutics, Inc., each a private biopharma company, and is retired from a distinguished career with Eli Lilly and Company. He served as chairman of the board of directors of AMAG Pharmaceuticals, Inc., previously a public biopharma company, from February 2012 until November 2020, when AMAG was acquired by Covis Group S. à r.l., and on the board of directors of Allena Pharmaceuticals, Inc., a public biopharma company, from February 2012 until September 2022. During his tenure at Eli Lilly and Company from June 1983 to December 2010, Mr. Santini held various leadership positions. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master of business administration degree from the University of Rochester. - Gino Santini，自2012年3月起在董事会任职。目前，他在 AMAG Pharmaceuticals有限公司和Allena Pharmaceuticals有限公司董事会任职，且从Eli Lilly and Company（Lilly）退休，在此他工作了30年之久。在Lilly的任期内，他担任了责任越来越大的职务，包括许多国际地区的经理、女性健康特许的总裁，以及美国运营总裁。他在Lilly担任公司执行委员会董事及企业战略和业务发展高级副总裁。他精通四门语言，且持有博洛尼亚大学（ the University of Bologna）机械工程学士学位和罗切斯特大学（ the University of Rochester）工商管理硕士学位。
- Gino Santini,currently serves on the boards of directors of Intercept Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., both of which are public biopharma companies. Mr. Santini also serves on the boards of directors of Artax Biopharma Inc. and Enalare Therapeutics, Inc., each a private biopharma company, and is retired from a distinguished career with Eli Lilly and Company. He served as chairman of the board of directors of AMAG Pharmaceuticals, Inc., previously a public biopharma company, from February 2012 until November 2020, when AMAG was acquired by Covis Group S. à r.l., and on the board of directors of Allena Pharmaceuticals, Inc., a public biopharma company, from February 2012 until September 2022. During his tenure at Eli Lilly and Company from June 1983 to December 2010, Mr. Santini held various leadership positions. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master of business administration degree from the University of Rochester.
- Pascale Witz
-
Pascale Witz持有Institut National des Sciences Appliquées Lyon的生命科学/分子生物学硕士学位和欧洲工商管理学院（INSEAD）的工商管理硕士学位。她在研究实验室开始她的职业生涯（在1991年移到Becton Dickinson France的营销之前）。她于1996年加入GE Healthcare。在GEHC的职业生涯中，她领导许多业务。她是信息技术的副总裁，六西格玛和质量（Six Sigma and Quality）的副总裁（从2000年到2001年），核医学和PET的总经理（从2002年到2004年），销售&营销服务的副总裁（从2005年到2006年），计算机断层扫描的总经理（从2006年到2007年），法国和美国全球介入业务的副总裁和总经理（从2008年到2009年）。2009年她被任命为医学诊断业务的总裁和首席执行官。她成为Sanofi执行委员会（Executive Committee）的成员，2013年7月被任命到她现在的职位。
Pascale Witz,founded PWH Advisors, a strategic consultancy firm advising healthcare and investment companies, in November 2016 and has served as its president since that time. From September 2015 to May 2016, Ms. Witz served as executive vice president, global diabetes and cardiovascular at Sanofi, a pharmaceutical company, which she joined in July 2013 as executive vice president, pharma and CHC divisions. During her tenure at Sanofi, she launched multiple medicines across three continents and strengthened the pipeline through licensing and partnerships. Prior to Sanofi, Ms. Witz served more than 17 years at GE Healthcare where, in her final role as president and chief executive officer of its pharmaceutical diagnostics business, she ran a $2 billion integrated pharmaceutical organization that encompassed research and development through commercialization. Ms. Witz also serves on the boards of directors of Fresenius Medical Care AG & Co. KGaA, a public medical supply company; Regulus Therapeutics Inc., a public biotechnology company; Revvity, Inc., a public company focused on diagnostics and life science tools; PWH Advisors; Arkuda Therapeutics, Inc., a private biopharma company; CellCarta Biosciences, a private biopharma services company; WGC Clinical Services, a private biopharma services company; and Lumanity Inc., a private technology company. She also serves as chair of RTI Surgical, Inc., a private biologics implants company. Ms. Witz previously served on the board of directors of Savencia SA, a public food and dairy company, from 2016 to 2018, and of Tesaro, Inc., then a public biopharma company, from 2018 to January 2019. Ms. Witz received her master of business administration degree in economics and marketing from INSEAD and her master of science in biochemistry from INSA Lyon. In 2023, Ms. Witz holds a CERT Certificate in Cybersecurity Oversight from the Software Engineering Institute of Carnegie Mellon University and the National Association of Corporate Directors, which she earned in 2022. - Pascale Witz持有Institut National des Sciences Appliquées Lyon的生命科学/分子生物学硕士学位和欧洲工商管理学院（INSEAD）的工商管理硕士学位。她在研究实验室开始她的职业生涯（在1991年移到Becton Dickinson France的营销之前）。她于1996年加入GE Healthcare。在GEHC的职业生涯中，她领导许多业务。她是信息技术的副总裁，六西格玛和质量（Six Sigma and Quality）的副总裁（从2000年到2001年），核医学和PET的总经理（从2002年到2004年），销售&营销服务的副总裁（从2005年到2006年），计算机断层扫描的总经理（从2006年到2007年），法国和美国全球介入业务的副总裁和总经理（从2008年到2009年）。2009年她被任命为医学诊断业务的总裁和首席执行官。她成为Sanofi执行委员会（Executive Committee）的成员，2013年7月被任命到她现在的职位。
- Pascale Witz,founded PWH Advisors, a strategic consultancy firm advising healthcare and investment companies, in November 2016 and has served as its president since that time. From September 2015 to May 2016, Ms. Witz served as executive vice president, global diabetes and cardiovascular at Sanofi, a pharmaceutical company, which she joined in July 2013 as executive vice president, pharma and CHC divisions. During her tenure at Sanofi, she launched multiple medicines across three continents and strengthened the pipeline through licensing and partnerships. Prior to Sanofi, Ms. Witz served more than 17 years at GE Healthcare where, in her final role as president and chief executive officer of its pharmaceutical diagnostics business, she ran a $2 billion integrated pharmaceutical organization that encompassed research and development through commercialization. Ms. Witz also serves on the boards of directors of Fresenius Medical Care AG & Co. KGaA, a public medical supply company; Regulus Therapeutics Inc., a public biotechnology company; Revvity, Inc., a public company focused on diagnostics and life science tools; PWH Advisors; Arkuda Therapeutics, Inc., a private biopharma company; CellCarta Biosciences, a private biopharma services company; WGC Clinical Services, a private biopharma services company; and Lumanity Inc., a private technology company. She also serves as chair of RTI Surgical, Inc., a private biologics implants company. Ms. Witz previously served on the board of directors of Savencia SA, a public food and dairy company, from 2016 to 2018, and of Tesaro, Inc., then a public biopharma company, from 2018 to January 2019. Ms. Witz received her master of business administration degree in economics and marketing from INSEAD and her master of science in biochemistry from INSA Lyon. In 2023, Ms. Witz holds a CERT Certificate in Cybersecurity Oversight from the Software Engineering Institute of Carnegie Mellon University and the National Association of Corporate Directors, which she earned in 2022.
- H. Thomas Watkins
-
H. Thomas Watkins，他是私人生物技术公司hemshear Therapeutics LLC的董事会成员。从2004年到2012年被GlaxoSmithKline收购，他担任人类基因组科学公司（HGS）的董事、总裁兼首席执行官，这是一家公共生物制药公司。在领导HGS之前，Watkins先生在Abbott及其在美国和亚洲的附属公司担任高级职务超过20年，最近担任TAP Pharmaceutical Products, Inc. （TAP）的总裁，该公司由Abbott和akeda Pharmaceutical Company, Inc.共同拥有。在他任职期间，他领导TAP的年收入从大约20亿美元增长到超过40亿美元。他于1974年在Arthur Andersen & Co.开始他的职业生涯。从1979年到1985年，他是McKinsey and Company, Inc.的管理顾问，与美国、欧洲和日本的跨国公司合作。2006年9月至2022年6月，他曾担任公共生物制药公司Vanda Pharmaceuticals Inc.的董事会成员。他持有William and Mary的学士学位，以及芝加哥大学商学院的工商管理硕士学位。Watkins先生正在完成Carnegie Mellon University软件工程学院和全国企业董事协会颁发的网络安全监督CERT证书。
H. Thomas Watkins,is a member of the board of directors of HemoShear Therapeutics LLC, a private biotechnology company. He was director, president and chief executive officer of Human Genome Sciences, Inc. (HGS), a public biopharma company, from 2004 until HGS was acquired by GlaxoSmithKline in 2012. Before leading HGS, Mr. Watkins spent over twenty years in senior roles at Abbott and its affiliates in the United States and Asia, most recently serving as the president of TAP Pharmaceutical Products, Inc. (TAP), which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc. During his tenure, he led the growth of TAP from approximately $2 billion to over $4 billion in annual revenue. Mr. Watkins began his career in 1974 with Arthur Andersen & Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the United States, Europe and Japan. Mr. Watkins previously served on the board of directors of Vanda Pharmaceuticals Inc., a public biopharma company, from September 2006 until June 2022. He holds a bachelor's degree from William and Mary, and a master of business administration degree from the University of Chicago Graduate School of Business. Mr. Watkins is in the process of completing the CERT Certificate in Cybersecurity Oversight from the Software Engineering Institute of Carnegie Mellon University and the National Association of Corporate Directors. - H. Thomas Watkins，他是私人生物技术公司hemshear Therapeutics LLC的董事会成员。从2004年到2012年被GlaxoSmithKline收购，他担任人类基因组科学公司（HGS）的董事、总裁兼首席执行官，这是一家公共生物制药公司。在领导HGS之前，Watkins先生在Abbott及其在美国和亚洲的附属公司担任高级职务超过20年，最近担任TAP Pharmaceutical Products, Inc. （TAP）的总裁，该公司由Abbott和akeda Pharmaceutical Company, Inc.共同拥有。在他任职期间，他领导TAP的年收入从大约20亿美元增长到超过40亿美元。他于1974年在Arthur Andersen & Co.开始他的职业生涯。从1979年到1985年，他是McKinsey and Company, Inc.的管理顾问，与美国、欧洲和日本的跨国公司合作。2006年9月至2022年6月，他曾担任公共生物制药公司Vanda Pharmaceuticals Inc.的董事会成员。他持有William and Mary的学士学位，以及芝加哥大学商学院的工商管理硕士学位。Watkins先生正在完成Carnegie Mellon University软件工程学院和全国企业董事协会颁发的网络安全监督CERT证书。
- H. Thomas Watkins,is a member of the board of directors of HemoShear Therapeutics LLC, a private biotechnology company. He was director, president and chief executive officer of Human Genome Sciences, Inc. (HGS), a public biopharma company, from 2004 until HGS was acquired by GlaxoSmithKline in 2012. Before leading HGS, Mr. Watkins spent over twenty years in senior roles at Abbott and its affiliates in the United States and Asia, most recently serving as the president of TAP Pharmaceutical Products, Inc. (TAP), which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc. During his tenure, he led the growth of TAP from approximately $2 billion to over $4 billion in annual revenue. Mr. Watkins began his career in 1974 with Arthur Andersen & Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the United States, Europe and Japan. Mr. Watkins previously served on the board of directors of Vanda Pharmaceuticals Inc., a public biopharma company, from September 2006 until June 2022. He holds a bachelor's degree from William and Mary, and a master of business administration degree from the University of Chicago Graduate School of Business. Mr. Watkins is in the process of completing the CERT Certificate in Cybersecurity Oversight from the Software Engineering Institute of Carnegie Mellon University and the National Association of Corporate Directors.
高管简历
中英对照 | 中文 | 英文- Michael A. DesJardin
Michael A.Desjardin自2017年2月起担任我们的执行Vice President，技术运营和企业质量。Desjardin先生曾于2016年10月至2016年11月担任我们的高级副总裁，技术运营，并于2016年12月至2017年1月担任我们的高级副总裁，生命周期管理。Desjardin先生于2016年10月从Raptor加入Horizon，作为收购Raptor的一部分。在Raptor任职期间，Desjardin先生于2015年4月至2016年10月担任技术运营高级副总裁。在此之前，Desjardin先生于2015年7月至3月担任Jazz Pharmaceuticals Public Limited Company（前身为Jazz Pharmaceuticals，Inc.，Jazz）产品开发高级副总裁。Desjardin先生在ALZA Corporation担任了9年的执行董事和工程研究员，并在陶氏化学公司工作了15年，为Marion Merrill Dow从事制药和农用化学品开发。Desjardin先生拥有超过39年的制药开发经验。Desjardin先生在加州大学伯克利分校（University of California，Berkeley）获得化学工程理学士学位，是加利福尼亚州的注册专业工程师。
Michael A. DesJardin,has served as Horizon Therapeutics Public Limited Company executive vice president, technical operations and corporate quality since February 2017. Mr. DesJardin previously served as Horizon Therapeutics Public Limited Company senior vice president, technical operations from October 2016 to November 2016 and as Horizon Therapeutics Public Limited Company senior vice president, life cycle management from December 2016 to January 2017. Mr. DesJardin joined Horizon from Raptor Pharmaceutical Corp. (Raptor), a public biopharma company, in October 2016 as part of the Raptor acquisition. While at Raptor, Mr. DesJardin was the senior vice president of technical operations from April 2015 to October 2016. Prior to that, Mr. DesJardin served as senior vice president of product development at Jazz Pharmaceuticals plc (formerly Jazz Pharmaceuticals, Inc.) from July 2004 to March 2015. Mr. DesJardin spent nine years as an executive director and engineering fellow at ALZA Corporation and spent 15 years at the Dow Chemical Company working in pharmaceutical and agricultural chemical development for Marion Merrill Dow. Mr. DesJardin received a bachelor of science degree in chemical engineering from the University of California, Berkeley, and is a registered professional engineer in the State of California.- Michael A.Desjardin自2017年2月起担任我们的执行Vice President，技术运营和企业质量。Desjardin先生曾于2016年10月至2016年11月担任我们的高级副总裁，技术运营，并于2016年12月至2017年1月担任我们的高级副总裁，生命周期管理。Desjardin先生于2016年10月从Raptor加入Horizon，作为收购Raptor的一部分。在Raptor任职期间，Desjardin先生于2015年4月至2016年10月担任技术运营高级副总裁。在此之前，Desjardin先生于2015年7月至3月担任Jazz Pharmaceuticals Public Limited Company（前身为Jazz Pharmaceuticals，Inc.，Jazz）产品开发高级副总裁。Desjardin先生在ALZA Corporation担任了9年的执行董事和工程研究员，并在陶氏化学公司工作了15年，为Marion Merrill Dow从事制药和农用化学品开发。Desjardin先生拥有超过39年的制药开发经验。Desjardin先生在加州大学伯克利分校（University of California，Berkeley）获得化学工程理学士学位，是加利福尼亚州的注册专业工程师。
- Michael A. DesJardin,has served as Horizon Therapeutics Public Limited Company executive vice president, technical operations and corporate quality since February 2017. Mr. DesJardin previously served as Horizon Therapeutics Public Limited Company senior vice president, technical operations from October 2016 to November 2016 and as Horizon Therapeutics Public Limited Company senior vice president, life cycle management from December 2016 to January 2017. Mr. DesJardin joined Horizon from Raptor Pharmaceutical Corp. (Raptor), a public biopharma company, in October 2016 as part of the Raptor acquisition. While at Raptor, Mr. DesJardin was the senior vice president of technical operations from April 2015 to October 2016. Prior to that, Mr. DesJardin served as senior vice president of product development at Jazz Pharmaceuticals plc (formerly Jazz Pharmaceuticals, Inc.) from July 2004 to March 2015. Mr. DesJardin spent nine years as an executive director and engineering fellow at ALZA Corporation and spent 15 years at the Dow Chemical Company working in pharmaceutical and agricultural chemical development for Marion Merrill Dow. Mr. DesJardin received a bachelor of science degree in chemical engineering from the University of California, Berkeley, and is a registered professional engineer in the State of California.
- Andy Pasternak
Andy Pasternak自2020年3月起担任我们的执行Vice President兼首席战略官，此前曾于2019年11月至2020年3月担任我们的执行Vice President兼首席商务官。在加入Horizon之前，Pasternak先生曾于2008年至2019年10月担任全球管理咨询公司贝恩公司（Bain&Company，Inc.）的合伙人，最近领导贝恩公司（Bain&Company&8217；）在美洲的梦百合业务，并是并购业务的成员。Pasternak先生在芝加哥大学（University of Chicago）获得工商管理硕士学位，在西北大学（Northwestern University）获得经济学文学学士学位。
Andy Pasternak,has served as Horizon Therapeutics Public Limited Company executive vice president, chief strategy officer since March 2020 and previously served as Horizon Therapeutics Public Limited Company executive vice president, chief business officer from November 2019 until March 2020. Prior to joining Horizon, Mr. Pasternak served as a partner of Bain & Company, Inc., a global management consulting firm, from 2008 until October 2019, where he most recently led Bain & Company's healthcare practice in the Americas and was a member of the mergers and acquisition practice. Mr. Pasternak earned a master of business administration degree from the University of Chicago and a bachelor of arts degree in economics from Northwestern University.- Andy Pasternak自2020年3月起担任我们的执行Vice President兼首席战略官，此前曾于2019年11月至2020年3月担任我们的执行Vice President兼首席商务官。在加入Horizon之前，Pasternak先生曾于2008年至2019年10月担任全球管理咨询公司贝恩公司（Bain&Company，Inc.）的合伙人，最近领导贝恩公司（Bain&Company&8217；）在美洲的梦百合业务，并是并购业务的成员。Pasternak先生在芝加哥大学（University of Chicago）获得工商管理硕士学位，在西北大学（Northwestern University）获得经济学文学学士学位。
- Andy Pasternak,has served as Horizon Therapeutics Public Limited Company executive vice president, chief strategy officer since March 2020 and previously served as Horizon Therapeutics Public Limited Company executive vice president, chief business officer from November 2019 until March 2020. Prior to joining Horizon, Mr. Pasternak served as a partner of Bain & Company, Inc., a global management consulting firm, from 2008 until October 2019, where he most recently led Bain & Company's healthcare practice in the Americas and was a member of the mergers and acquisition practice. Mr. Pasternak earned a master of business administration degree from the University of Chicago and a bachelor of arts degree in economics from Northwestern University.
- Sean M. Clayton
肖恩·M·克莱顿，自2022年2月起担任Horizon Therapeutics Public Limited Company执行副总裁兼总法律顾问。在加入Horizon之前，克莱顿是Cooley LLP律师事务所的合伙人，该律师事务所是一家全球性的律师事务所，他从2004年10月至2022年2月在这里执业，最近担任该事务所圣地亚哥公司业务主管。在此之前，克莱顿曾担任美国加州南区联邦地区法院法官伊尔玛·E·冈萨雷斯（Irma E. Gonzalez，退休）的法律助理。Clayton先生在加州大学圣迭戈分校获得政治学和经济学学士学位，在斯坦福大学法学院获得法学博士学位。
Sean M. Clayton,has served as Horizon Therapeutics Public Limited Company executive vice president, general counsel since February 2022. Prior to joining Horizon, Mr. Clayton was a partner at Cooley LLP, a global law firm, where he practiced from October 2004 until February 2022, most recently as the head of the firm's San Diego corporate practice. Before that, Mr. Clayton served as a law clerk to Judge Irma E. Gonzalez (Ret.) of the U.S. District Court for the Southern District of California. Mr. Clayton received a bachelor of arts degree in political science and economics from the University of California, San Diego and a juris doctorate degree from Stanford Law School.- 肖恩·M·克莱顿，自2022年2月起担任Horizon Therapeutics Public Limited Company执行副总裁兼总法律顾问。在加入Horizon之前，克莱顿是Cooley LLP律师事务所的合伙人，该律师事务所是一家全球性的律师事务所，他从2004年10月至2022年2月在这里执业，最近担任该事务所圣地亚哥公司业务主管。在此之前，克莱顿曾担任美国加州南区联邦地区法院法官伊尔玛·E·冈萨雷斯（Irma E. Gonzalez，退休）的法律助理。Clayton先生在加州大学圣迭戈分校获得政治学和经济学学士学位，在斯坦福大学法学院获得法学博士学位。
- Sean M. Clayton,has served as Horizon Therapeutics Public Limited Company executive vice president, general counsel since February 2022. Prior to joining Horizon, Mr. Clayton was a partner at Cooley LLP, a global law firm, where he practiced from October 2004 until February 2022, most recently as the head of the firm's San Diego corporate practice. Before that, Mr. Clayton served as a law clerk to Judge Irma E. Gonzalez (Ret.) of the U.S. District Court for the Southern District of California. Mr. Clayton received a bachelor of arts degree in political science and economics from the University of California, San Diego and a juris doctorate degree from Stanford Law School.
- Aaron L. Cox
Aaron L. Cox，自2022年5月起担任Horizon Therapeutics Public Limited Company执行副总裁兼首席财务官。考克斯先生曾于2021年11月至2022年5月担任财务执行副总裁；于2017年7月至2021年11月担任企业发展高级副总裁，此外还担任Timothy P. Walbert的幕僚长；于2017年5月至2017年7月担任业务发展高级总监；于2016年4月至2017年5月担任业务发展总监。在2016年4月加入Horizon之前，Cox先生曾于2012年7月至2016年4月在BMO资本市场担任资本市场副总裁，在此之前，他曾于2007年至2010年在Stout和2005年至2006年在JMP证券担任投资银行职务。Cox先生在芝加哥大学获得工商管理硕士学位，在圣母大学获得金融工商管理学士学位。
Aaron L. Cox,has served as Horizon Therapeutics Public Limited Company executive vice president, chief financial officer since May 2022. Mr. Cox previously served as executive vice president, finance from November 2021 to May 2022; as senior vice president, corporate development, in addition to serving as chief of staff for Timothy P. Walbert, from July 2017 to November 2021; as senior director, business development, from May 2017 to July 2017 and as director, business development from April 2016 to May 2017. Prior to joining Horizon in April 2016, Mr. Cox served as vice president, capital markets at BMO Capital Markets from July 2012 to April 2016, and before that, he held investment banking roles at Stout from 2007 to 2010 and JMP Securities from 2005 to 2006. Mr. Cox received a master of business administration from the University of Chicago and a bachelor of business administration in finance from the University of Notre Dame.- Aaron L. Cox，自2022年5月起担任Horizon Therapeutics Public Limited Company执行副总裁兼首席财务官。考克斯先生曾于2021年11月至2022年5月担任财务执行副总裁；于2017年7月至2021年11月担任企业发展高级副总裁，此外还担任Timothy P. Walbert的幕僚长；于2017年5月至2017年7月担任业务发展高级总监；于2016年4月至2017年5月担任业务发展总监。在2016年4月加入Horizon之前，Cox先生曾于2012年7月至2016年4月在BMO资本市场担任资本市场副总裁，在此之前，他曾于2007年至2010年在Stout和2005年至2006年在JMP证券担任投资银行职务。Cox先生在芝加哥大学获得工商管理硕士学位，在圣母大学获得金融工商管理学士学位。
- Aaron L. Cox,has served as Horizon Therapeutics Public Limited Company executive vice president, chief financial officer since May 2022. Mr. Cox previously served as executive vice president, finance from November 2021 to May 2022; as senior vice president, corporate development, in addition to serving as chief of staff for Timothy P. Walbert, from July 2017 to November 2021; as senior director, business development, from May 2017 to July 2017 and as director, business development from April 2016 to May 2017. Prior to joining Horizon in April 2016, Mr. Cox served as vice president, capital markets at BMO Capital Markets from July 2012 to April 2016, and before that, he held investment banking roles at Stout from 2007 to 2010 and JMP Securities from 2005 to 2006. Mr. Cox received a master of business administration from the University of Chicago and a bachelor of business administration in finance from the University of Notre Dame.
- Elizabeth H.Z. Thompson
Elizabeth H.Z. Thompson，自2021年3月起担任Horizon Therapeutics Public Limited Company执行副总裁，负责研发。她曾于2020年1月至2021年3月担任Horizon Therapeutics Public Limited Company集团副总裁，负责开发和外部搜索，并于2018年6月至2020年1月担任Horizon Therapeutics Public Limited Company副总裁，负责临床开发（罕见病）。在加入Horizon之前，她于2017年4月至2018年5月在艾伯维担任临床开发团队科学总监，并于2015年9月至2017年4月担任临床开发高级科学总监。在艾伯维任职期间，她是risankizumab（SKYRIZI）的临床负责人，支持全球提交和批准。在加入艾伯维之前，汤普森博士曾在Raptor、InterMune和安进任职，职业生涯涵盖临床开发、商业发展和医疗交流。汤普森博士在哈维穆德学院获得化学理学士学位，在斯克里普斯研究所获得大分子和细胞结构及化学博士学位。
Elizabeth H.Z. Thompson,has served as Horizon Therapeutics Public Limited Company executive vice president, research and development since March 2021. Previously she served as Horizon Therapeutics Public Limited Company group vice president, development and external search from January 2020 to March 2021, and as Horizon Therapeutics Public Limited Company vice president, clinical development (rare disease) from June 2018 to January 2020. Prior to joining Horizon, she was with AbbVie as group scientific director, clinical development from April 2017 to May 2018 and senior scientific director, clinical development, from September 2015 to April 2017. While at AbbVie, she was the clinical lead for risankizumab (SKYRIZI), supporting global submissions and approvals. Before AbbVie, Dr. Thompson held roles at Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications. Dr. Thompson received a bachelor of science degree in chemistry from Harvey Mudd College and a doctorate in macromolecular and cellular structure and chemistry from The Scripps Research Institute.- Elizabeth H.Z. Thompson，自2021年3月起担任Horizon Therapeutics Public Limited Company执行副总裁，负责研发。她曾于2020年1月至2021年3月担任Horizon Therapeutics Public Limited Company集团副总裁，负责开发和外部搜索，并于2018年6月至2020年1月担任Horizon Therapeutics Public Limited Company副总裁，负责临床开发（罕见病）。在加入Horizon之前，她于2017年4月至2018年5月在艾伯维担任临床开发团队科学总监，并于2015年9月至2017年4月担任临床开发高级科学总监。在艾伯维任职期间，她是risankizumab（SKYRIZI）的临床负责人，支持全球提交和批准。在加入艾伯维之前，汤普森博士曾在Raptor、InterMune和安进任职，职业生涯涵盖临床开发、商业发展和医疗交流。汤普森博士在哈维穆德学院获得化学理学士学位，在斯克里普斯研究所获得大分子和细胞结构及化学博士学位。
- Elizabeth H.Z. Thompson,has served as Horizon Therapeutics Public Limited Company executive vice president, research and development since March 2021. Previously she served as Horizon Therapeutics Public Limited Company group vice president, development and external search from January 2020 to March 2021, and as Horizon Therapeutics Public Limited Company vice president, clinical development (rare disease) from June 2018 to January 2020. Prior to joining Horizon, she was with AbbVie as group scientific director, clinical development from April 2017 to May 2018 and senior scientific director, clinical development, from September 2015 to April 2017. While at AbbVie, she was the clinical lead for risankizumab (SKYRIZI), supporting global submissions and approvals. Before AbbVie, Dr. Thompson held roles at Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications. Dr. Thompson received a bachelor of science degree in chemistry from Harvey Mudd College and a doctorate in macromolecular and cellular structure and chemistry from The Scripps Research Institute.
- Timothy P. Walbert
Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania.- Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
- Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania.
- Jeffrey W. Sherman
Jeffrey W. Sherman，自2018年1月起担任Horizon Therapeutics Public Limited公司执行副总裁兼首席医疗官。2014年9月至2018年1月，他担任Horizon Therapeutics Public Limited Company执行副总裁，负责研发和首席医疗官。他于2009年加入Horizon，担任Horizon Therapeutics Public Limited Company的执行副总裁，负责开发、制造、监管事务和首席医疗官。加入Horizon之前，他曾担任药物信息协会（DIA）的总裁和董事会成员，这是一个非营利性的专业协会，成员在政府监管、学术界、患者倡导以及制药和医疗器械行业工作。在此之前，他曾在IDM Pharma, Inc.， Takeda Global Research & Development, NeoPharm, Inc.和G.D. Searle, LLC/Pharmacia担任其他管理职务。他担任公共生物制药公司Xeris BioPharma Holdings, Inc. （Xeris BioPharma）的董事会成员，此前曾担任Strongbridge BioPharma plc的董事会成员（2016年10月至2021年10月）和Xeris Pharmaceuticals Inc. （Xeris）的董事会成员（2018年4月至2021年10月）。Xeris于2021年10月收购了Strongbridge，与此相关，Xeris和Strongbridge成为Xeris BioPharma的全资子公司。他还担任Sorriso Pharmaceuticals, Inc.（一家私营生物技术公司）的董事会，生物技术创新组织（BIO）健康部门管理委员会和临床研究参与信息和研究中心（CISCRP）的顾问委员会。他是西北大学Feinberg School of Medicine的兼职助理教授，也是美国国家医学检验委员会和美国内科医学委员会的外交官。他获得了Rosalind Franklin University/ Chicago Medical School的医学学位。
Jeffrey W. Sherman,has served as Horizon Therapeutics Public Limited Company executive vice president, chief medical officer since January 2018. From September 2014 to January 2018, Dr. Sherman served as Horizon Therapeutics Public Limited Company executive vice president, research and development and chief medical officer. He joined Horizon in 2009 as Horizon Therapeutics Public Limited Company executive vice president, development, manufacturing, regulatory affairs and chief medical officer. Prior to joining Horizon, Dr. Sherman served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Before that he held other management roles at IDM Pharma, Inc., Takeda Global Research & Development, NeoPharm, Inc. and G.D. Searle, LLC/Pharmacia. Dr. Sherman serves on the board of directors of Xeris BioPharma Holdings, Inc., a public biopharmaceutical company (Xeris BioPharma), and previously served on the board of directors of Strongbridge Biopharma plc from October 2016 until October 2021 and Xeris Pharmaceuticals Inc. (Xeris) from April 2018 until October 2021. Xeris acquired Strongbridge in October 2021 and in connection therewith both Xeris and Strongbridge became wholly owned subsidiaries of Xeris BioPharma. He also serves on the board of directors of Sorriso Pharmaceuticals, Inc., a private biotechnology company, the Biotechnology Innovation Organization (BIO) Health Section Governing Board and the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP). He is an adjunct assistant professor of Medicine at the Northwestern University Feinberg School of Medicine and a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. Dr. Sherman received his medical degree from the Rosalind Franklin University/ Chicago Medical School.- Jeffrey W. Sherman，自2018年1月起担任Horizon Therapeutics Public Limited公司执行副总裁兼首席医疗官。2014年9月至2018年1月，他担任Horizon Therapeutics Public Limited Company执行副总裁，负责研发和首席医疗官。他于2009年加入Horizon，担任Horizon Therapeutics Public Limited Company的执行副总裁，负责开发、制造、监管事务和首席医疗官。加入Horizon之前，他曾担任药物信息协会（DIA）的总裁和董事会成员，这是一个非营利性的专业协会，成员在政府监管、学术界、患者倡导以及制药和医疗器械行业工作。在此之前，他曾在IDM Pharma, Inc.， Takeda Global Research & Development, NeoPharm, Inc.和G.D. Searle, LLC/Pharmacia担任其他管理职务。他担任公共生物制药公司Xeris BioPharma Holdings, Inc. （Xeris BioPharma）的董事会成员，此前曾担任Strongbridge BioPharma plc的董事会成员（2016年10月至2021年10月）和Xeris Pharmaceuticals Inc. （Xeris）的董事会成员（2018年4月至2021年10月）。Xeris于2021年10月收购了Strongbridge，与此相关，Xeris和Strongbridge成为Xeris BioPharma的全资子公司。他还担任Sorriso Pharmaceuticals, Inc.（一家私营生物技术公司）的董事会，生物技术创新组织（BIO）健康部门管理委员会和临床研究参与信息和研究中心（CISCRP）的顾问委员会。他是西北大学Feinberg School of Medicine的兼职助理教授，也是美国国家医学检验委员会和美国内科医学委员会的外交官。他获得了Rosalind Franklin University/ Chicago Medical School的医学学位。
- Jeffrey W. Sherman,has served as Horizon Therapeutics Public Limited Company executive vice president, chief medical officer since January 2018. From September 2014 to January 2018, Dr. Sherman served as Horizon Therapeutics Public Limited Company executive vice president, research and development and chief medical officer. He joined Horizon in 2009 as Horizon Therapeutics Public Limited Company executive vice president, development, manufacturing, regulatory affairs and chief medical officer. Prior to joining Horizon, Dr. Sherman served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Before that he held other management roles at IDM Pharma, Inc., Takeda Global Research & Development, NeoPharm, Inc. and G.D. Searle, LLC/Pharmacia. Dr. Sherman serves on the board of directors of Xeris BioPharma Holdings, Inc., a public biopharmaceutical company (Xeris BioPharma), and previously served on the board of directors of Strongbridge Biopharma plc from October 2016 until October 2021 and Xeris Pharmaceuticals Inc. (Xeris) from April 2018 until October 2021. Xeris acquired Strongbridge in October 2021 and in connection therewith both Xeris and Strongbridge became wholly owned subsidiaries of Xeris BioPharma. He also serves on the board of directors of Sorriso Pharmaceuticals, Inc., a private biotechnology company, the Biotechnology Innovation Organization (BIO) Health Section Governing Board and the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP). He is an adjunct assistant professor of Medicine at the Northwestern University Feinberg School of Medicine and a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. Dr. Sherman received his medical degree from the Rosalind Franklin University/ Chicago Medical School.